Breaking News Instant updates and real-time market news.

CTMX

CytomX Therapeutics

$25.27

0.59 (2.39%)

, XNCR

Xencor

$41.66

(0.00%)

07:34
06/14/18
06/14
07:34
06/14/18
07:34

CytomX Therapeutics appoints Lloyd Rowland Jr. as general counsel

CytomX Therapeutics (CTMX) announced the appointment of Lloyd Rowland, Jr. as SVP, general counsel. Rowland brings to CytomX 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience. Most recently, Rowland held the position of SVP, general counsel and chief compliance officer of Xencor (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer.

CTMX

CytomX Therapeutics

$25.27

0.59 (2.39%)

XNCR

Xencor

$41.66

(0.00%)

  • 20

    Jun

CTMX CytomX Therapeutics
$25.27

0.59 (2.39%)

03/08/18
JEFF
03/08/18
NO CHANGE
Target $40
JEFF
Buy
CytomX Therapeutics price target raised to $40 from $25 at Jefferies
Jefferies analyst Biren Amin raised his price target for CytomX Therapeutics to $40 following the company's Q4 report and ahead of "multiple readouts" in 2018 expected from CX-072 and CX-2009. The analyst keeps a Buy rating on the shares.
06/01/18
RHCO
06/01/18
INITIATION
Target $38
RHCO
Buy
CytomX Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Peter Lawson initiated CytomX Therapeutics with a Buy rating and $38 price target. In a research note to investors, Lawson said he is "encouraged" by the biopharma validation of CytomX's platform, while the company retains ownership of a major part of its pipeline, and believes ASCO and 2H data validates the CX-072 platform for safety and efficacy. Additionally, Lawson contends that 2H data for CX-2009 will validate the company's strategy of targeting "undruggable" antigens, unlocking two components of CytomX's valuation. Further, he believes three readouts in 2018 -- updated CX-027 data at ASCO, initial Phase 1/2 data from CX-2009 in the second half of the year, and follow-on Phase 1/2 data from CX-072 in the second half -- could be positive for the company.
06/04/18
NOMU
06/04/18
NO CHANGE
NOMU
Buy
CytomX selloff after ASCO presentations 'unfounded,' says Nomura Instinet
After CytomX Therapeutics presented two presentations for its Probody CX-072 at ASCO, Nomura Instinet analyst Christopher Marai said the data "unequivocally demonstrated" that CX-072 is performing as expected and the selloff in the stock is "unfounded." After discussing with study investigators the real-world experience with CX-072, they noted that despite small numbers it was clear that immune-related adverse events typically associated with anti-PD-L1 agents were reduced, added Marai, who reiterates a Buy rating on CytomX shares.
06/04/18
JEFF
06/04/18
NO CHANGE
Target $40
JEFF
Buy
CytomX early data point to some safety differentiation, says Jefferies
Jefferies analyst Biren Amin said he thinks some investors may have sought a better efficacy profile from CX-072. However, he notes that the Yervoy combo data provided at ASCO are in the dose-escalation phase and are in heavily pretreated patients, adding that safety seems improved with the CX-072 plus ipi combo. Amin has a Buy rating and $40 price target on CytomX shares, which are down $5.58, or 22%, to $19.96 in afternoon trading.
XNCR Xencor
$41.66

(0.00%)

04/05/18
NOMU
04/05/18
NO CHANGE
Target $28
NOMU
Neutral
Xencor price target lowered to $28 from $33 at Nomura Instinet
Nomura Instinet analyst Christopher Marai lowered his price target for Xencor to $28 to reflect dilution from the share offering that closed in March. The analyst keeps a Neutral rating on the shares.
04/26/18
PIPR
04/26/18
NO CHANGE
PIPR
Alexion data further validate Xencor platform, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes this morning's Phase III data for Alexion's (ALXN) long-acting C5 antibody ALXN1210 in paroxysmal nocturnal hemoglobinuria patients switching from Soliris validate Xencor's XmAb platform. Recall, ALXN1210 employs Xencor's Xtend antibody technology to extend half-life and reduce dosing frequency, Tenthoff tells investors in a research note. He believes, however, that the driver for Xencor this year remains the preliminary Phase I data for Novartis-partnered bispecifics in acute myeloid leukemia and B-cell malignancies. The analyst reiterates an Overweight rating on Xencor with a $46 price target.
06/06/18
BTIG
06/06/18
INITIATION
Target $56
BTIG
Buy
Xencor initiated with a Buy at BTIG
BTIG analyst Dane Leone started Xencor with a Buy rating and $56 price target. The analyst is optimistic for the use of XmAb5871 in the treatment of systemic lupus erythematosus into the Phase 2 read-out during the second half of 2018. Further, he believes the commercialization of Xencor's partner assets, ALXN1210 and MOR208, should help support its cash flow for the next several years.
06/07/18
06/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Xencor (XNCR) initiated with a Buy at BTIG. 2. Donnelley Financial Solutions (DFIN) initiated with a Buy at DA Davidson. 3. Axsome Therapeutics (AXSM) initiated with a Buy at H.C. Wainwright. 4. ShotSpotter (SSTI) initiated with an Outperform at JMP Securities. 5. WellCare (WCG) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

BECN

Beacon Roofing

$36.71

-0.72 (-1.92%)

15:37
09/25/18
09/25
15:37
09/25/18
15:37
Conference/Events
Beacon Roofing management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AIR

AAR Corp.

$45.94

0.95 (2.11%)

15:34
09/25/18
09/25
15:34
09/25/18
15:34
Options
AAR Corp. options imply 8.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SVMK

SurveyMonkey

$0.00

(0.00%)

15:33
09/25/18
09/25
15:33
09/25/18
15:33
Syndicate
SurveyMonkey aiming to price IPO above $9-$11 range, CNBC says »

CNBC cites sources on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ULTA

Ulta Beauty

$277.26

-3.75 (-1.33%)

15:25
09/25/18
09/25
15:25
09/25/18
15:25
Conference/Events
Cowen retail/luxury analyst to hold an analyst/industry conference call »

Retail/Luxury Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

CTAS

Cintas

$212.44

1.26 (0.60%)

15:19
09/25/18
09/25
15:19
09/25/18
15:19
Options
Cintas options imply 5.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
09/25/18
09/25
15:17
09/25/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
09/25/18
09/25
15:16
09/25/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$12.50

1.24 (11.01%)

15:12
09/25/18
09/25
15:12
09/25/18
15:12
Hot Stocks
FTE Networks CEO says on track to meet or exceed 2018 revenue view of $350M »

FTE Networks provided a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BX

Blackstone

$38.93

-0.77 (-1.94%)

, TRI

Thomson Reuters

$45.70

0.25 (0.55%)

15:11
09/25/18
09/25
15:11
09/25/18
15:11
Periodicals
Breaking Periodicals news story on Blackstone, Thomson Reuters »

Blackstone mulling sale…

BX

Blackstone

$38.93

-0.77 (-1.94%)

TRI

Thomson Reuters

$45.70

0.25 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 22

    Oct

WH

Wyndham Hotels & Resorts

$55.42

0.27 (0.49%)

15:10
09/25/18
09/25
15:10
09/25/18
15:10
Conference/Events
Wyndham Hotels & Resorts management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

JCI

Johnson Controls

$35.65

-0.58 (-1.60%)

15:10
09/25/18
09/25
15:10
09/25/18
15:10
Options
Notable call spread in Johnson Controls »

Notable call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:10
09/25/18
09/25
15:10
09/25/18
15:10
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

JBL

Jabil

$27.51

-2.57 (-8.54%)

15:08
09/25/18
09/25
15:08
09/25/18
15:08
Recommendations
Jabil analyst commentary  »

Jabil should be bought on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 13

    Nov

CMTL

Comtech

$34.73

0.77 (2.27%)

15:08
09/25/18
09/25
15:08
09/25/18
15:08
Hot Stocks
Comtech awarded over $4M in additional funding from U.S. Army »

Comtech announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

KBH

KB Home

$25.35

-0.18 (-0.71%)

15:04
09/25/18
09/25
15:04
09/25/18
15:04
Options
KB Home options imply 8.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MYGN

Myriad Genetics

$46.92

0.01 (0.02%)

15:00
09/25/18
09/25
15:00
09/25/18
15:00
Conference/Events
Myriad Genetics management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 06

    Nov

DAL

Delta Air Lines

$57.10

-0.33 (-0.57%)

15:00
09/25/18
09/25
15:00
09/25/18
15:00
Options
Delta draws a notable call spread as shares tick lower »

Delta draws a notable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

APRN

Blue Apron

$1.71

0.04 (2.40%)

14:57
09/25/18
09/25
14:57
09/25/18
14:57
Hot Stocks
Blue Apron jumps after O'Leary discusses on CNBC »

Shares of Blue Apron are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$200.71

-2.74 (-1.35%)

, CVS

CVS Health

$77.64

-1.1 (-1.40%)

14:54
09/25/18
09/25
14:54
09/25/18
14:54
Hot Stocks
NY DFS expresses concerns about proposed Aetna, CVS Health deal »

In a letter dated…

AET

Aetna

$200.71

-2.74 (-1.35%)

CVS

CVS Health

$77.64

-1.1 (-1.40%)

ESRX

Express Scripts

$93.26

-1.19 (-1.26%)

CI

Cigna

$200.54

-2.61 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 15

    Oct

ABT

Abbott

$72.00

0.57 (0.80%)

14:50
09/25/18
09/25
14:50
09/25/18
14:50
Hot Stocks
Abbott says study shows Portico safely reduced severe aortic stenosis »

Abbott announced one-year…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 17

    Oct

NKE

Nike

$85.02

0.75 (0.89%)

14:49
09/25/18
09/25
14:49
09/25/18
14:49
Options
Nike options imply 8.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EZPW

Ezcorp

$10.58

0.075 (0.71%)

14:45
09/25/18
09/25
14:45
09/25/18
14:45
Conference/Events
Ezcorp management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 06

    Nov

CNDT

Conduent

$22.30

0.12 (0.54%)

14:37
09/25/18
09/25
14:37
09/25/18
14:37
Conference/Events
Conduent management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

INTC

Intel

$46.14

-0.77 (-1.64%)

, ADI

Analog Devices

$92.82

-2.19 (-2.31%)

14:36
09/25/18
09/25
14:36
09/25/18
14:36
Hot Stocks
Intel slides as analyst says sell with semis seen in cyclical downturn »

Shares of Intel (INTC)…

INTC

Intel

$46.14

-0.77 (-1.64%)

ADI

Analog Devices

$92.82

-2.19 (-2.31%)

MCHP

Microchip

$79.10

-3.19 (-3.88%)

ON

ON Semiconductor

$18.44

-0.665 (-3.48%)

MPWR

Monolithic Power

$129.88

-2.99 (-2.25%)

AMD

AMD

$32.59

-0.03 (-0.09%)

NVDA

Nvidia

$268.05

2.33 (0.88%)

QCOM

Qualcomm

$73.16

-0.43 (-0.58%)

SIMO

Silicon Motion

$54.13

-0.04 (-0.07%)

MXIM

Maxim Integrated

$58.13

-1.61 (-2.70%)

TXN

Texas Instruments

$107.78

-2.03 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 04

    Oct

  • 08

    Oct

  • 22

    Oct

  • 10

    Dec

  • 08

    May

BRC

Brady

$44.20

0.15 (0.34%)

14:35
09/25/18
09/25
14:35
09/25/18
14:35
Hot Stocks
Brady director Elizabeth Bruno sells over $1M in company stock »

Brady director Elizabeth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.